• Explore /
  • Poster
  • / Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemotherapy randomization.

Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study—Analysis of patient reported outcomes (PRO) on chemotherapy randomization.

Abstract Poster

Authors

Karen Basen-Engquist

Karen Basen-Engquist

The University of Texas MD Anderson Cancer Center, Houston, TX

Karen Basen-Engquist , Helen Q Huang , Thomas J Herzog , Deborah Kay Armstrong , Paul Sabbatini , Joan L. Walker , Byoung Gie Kim , Keiichi Fujiwara , Krishnansu Sujata Tewari , David M. O'Malley , Robert L. Coleman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT00565851

Citation

J Clin Oncol 33, 2015 (suppl; abstr 5525)

DOI

10.1200/jco.2015.33.15_suppl.5525

Abstract #

5525

Poster Bd #

83

Abstract Disclosures

Similar Posters

First Author: Amreen Husain

First Author: Ronnie Shapira-Frommer

First Author: Jonathan Foote

First Author: Florian Heitz